week 21 check-in — 8kg down, fatigue manageable, one thing confusing me
week 21 check-in — 8kg down, fatigue manageable, one thing confusing me. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else.
Numbers, in the order they matter: week 21 and 8kg.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
How fast was the escalation? That is usually the variable that explains the reports.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
comparing reta phase 2 to sema phase 3 is comparing different things
the energy-expenditure story is mechanistically interesting and clinically unproven
phase 2 data only, and people quote it like it is a label
wait for phase 3 before you argue about rankings
the glucagon component is why the metabolic story reads differently
- 1Phase 2 estimates effect and finds a dose range. Phase 3 estimates it…9 comments in this branch · started by u/arne_amankwah